<?xml version="1.0" encoding="UTF-8"?>
<ListRecords>
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
  <dc:title>Therapeutic exchange of cefotaxime for ceftriaxone : evaluation, implementation, and subsequent cost savings at a 300-bed community hospital</dc:title>
  <dc:creator>RAWLINGS, R. D</dc:creator>
  <dc:contributor>Cefotaxime in the 90's : a workshop for appropriate broad-spectrum cephalosporin utilization</dc:contributor>
  <dc:relation>Diagnostic microbiology and infectious disease -- Diagn. microbiol. infect. dis, CODEN DMIDDZ, ISSN 0732-8893, Vol. 22 (1-2) , pp. 235-237</dc:relation>
  <dc:relation>Cefotaxime in the 90's : a workshop for appropriate broad-spectrum cephalosporin utilization</dc:relation>
  <dc:date>1995</dc:date>
  <dc:type>Text</dc:type>
  <dc:type>Conference Paper</dc:type>
  <dc:language>English</dc:language>
  <dc:publisher>Elsevier</dc:publisher>
  <dc:format>print</dc:format>
  <dc:format>6 ref</dc:format>
  <dc:subject xml:lang="fr">Activité biologique</dc:subject>
  <dc:subject xml:lang="fr">Analyse avantage coût</dc:subject>
  <dc:subject xml:lang="fr">Antibactérien</dc:subject>
  <dc:subject xml:lang="fr">Antibiotique</dc:subject>
  <dc:subject xml:lang="fr">Ceftriaxone</dc:subject>
  <dc:subject xml:lang="fr">Chimiothérapie</dc:subject>
  <dc:subject xml:lang="fr">Céfotaxime</dc:subject>
  <dc:subject xml:lang="fr">Céphalosporine dérivé</dc:subject>
  <dc:subject xml:lang="fr">Efficacité</dc:subject>
  <dc:subject xml:lang="fr">Evaluation performance</dc:subject>
  <dc:subject xml:lang="fr">Milieu hospitalier</dc:subject>
  <dc:subject xml:lang="fr">Traitement</dc:subject>
  <dc:subject xml:lang="en">Biological activity</dc:subject>
  <dc:subject xml:lang="en">Cost benefit analysis</dc:subject>
  <dc:subject xml:lang="en">Antibacterial agent</dc:subject>
  <dc:subject xml:lang="en">Antibiotic</dc:subject>
  <dc:subject xml:lang="en">Chemotherapy</dc:subject>
  <dc:subject xml:lang="en">Cephalosporin derivatives</dc:subject>
  <dc:subject xml:lang="en">Efficiency</dc:subject>
  <dc:subject xml:lang="en">Performance evaluation</dc:subject>
  <dc:subject xml:lang="en">Hospital environment</dc:subject>
  <dc:subject xml:lang="en">Treatment</dc:subject>
  <dc:subject xml:lang="es">Actividad biológica</dc:subject>
  <dc:subject xml:lang="es">Análisis costo beneficio</dc:subject>
  <dc:subject xml:lang="es">Antibacteriano</dc:subject>
  <dc:subject xml:lang="es">Antibiótico</dc:subject>
  <dc:subject xml:lang="es">Quimioterapia</dc:subject>
  <dc:subject xml:lang="es">Cefalosporina derivado</dc:subject>
  <dc:subject xml:lang="es">Eficacia</dc:subject>
  <dc:subject xml:lang="es">Evaluación prestación</dc:subject>
  <dc:subject xml:lang="es">Medio hospitalario</dc:subject>
  <dc:subject xml:lang="es">Tratamiento</dc:subject>
  <dc:subject>002B02S02: Antibactériens / Antibacterial agents</dc:subject>
  <dc:rights>Inist-CNRS</dc:rights>
  <dc:identifier>Inist-CNRS record number 3627068</dc:identifier>
  <dc:rights>Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS</dc:rights>
</metadata>
</ListRecords>